Molecular Templates Inc Stock News

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen

JPMorgan Chase & Co. boosted its position in shares of Molecular Templates Inc (NASDAQ:MTEM) by 1,852.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commissi

JPMorgan Chase & Co. lifted its holdings in shares of Molecular Templates Inc (NASDAQ:MTEM) by 1,852.3% in the first quarter, HoldingsChannel.com reports. The fund owned 108,979 shares of the biotechn

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time AUSTIN, Texas, June.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Shares of Molecular Templates Inc (NASDAQ:MTEM) have received a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. Two investment ana

Shares have risen by 157% since my 2018 recommendation and by 127% since my September update. Near term events include AACR II presentation (present new ETB pro

UBS Group AG trimmed its position in shares of Molecular Templates Inc (NASDAQ:MTEM) by 28.2% during the first quarter, HoldingsChannel reports. The fund owned 39,365 shares of the biotechnology compa

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Compan

AUSTIN, Texas,, May 15, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

AUSTIN, Texas, May 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates" or "MTEM"), a clinical-stage...

AUSTIN, Texas, May 13, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

AUSTIN, Texas, May 11, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery.

Molecular Templates, Inc. (the “Company”) (MTEM) announced today that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually due to the public health impact of t